FDA Accepts Resubmission for Dupixent to Treat Chronic Spontaneous Urticaria (CSU)

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (d...

November 18, 2024 | Monday | News
NurExone Gains EMA Orphan Designation for ExoPTEN, Advancing Spinal Cord Injury Therapy Across Europe

NurExone Biologic Inc.  a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the European Medici...

November 14, 2024 | Thursday | News
Stamford Health First in Connecticut to Offer AI-Powered Cardiovascular Screening Tool

Stamford Health's Heart & Vascular Institute has announced it will be the first in Connecticut to offer a new, AI-powered cardiovas...

November 12, 2024 | Tuesday | News
IASO Biotherapeutics’ Anti-BCMA CAR-T Therapy Fucaso™ Shows Strong Efficacy in Treating Relapsed/Refractory Multiple Myeloma in Phase 1b/2 Study Published in JAMA Oncology

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell ther...

November 08, 2024 | Friday | News
QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Cleared by FDA for Clinical Use

QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth ...

November 04, 2024 | Monday | News
Medtronic’s Symplicity Spyral™ Catheter Secures Transitional Pass-Through Payment from CMS

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that the Centers for Medicare & Medicaid Services (CMS) has granted...

November 04, 2024 | Monday | News
Novo Nordisk's SELECT Trial Reveals Semaglutide 2.4 mg Reduces Hospital Admissions for Patients with Obesity and Cardiovascular Disease

Novo Nordisk presented an exploratory post hoc analysis from the SELECT phase 3 cardiovascular outcomes trial that showed semaglutide 2.4 mg significantly ...

November 04, 2024 | Monday | News
Bristol Myers Squibb to Present New Data on COBENFY™ for Schizophrenia at Psych Congress 2024

Bristol Myers Squibb (NYSE: BMY) announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio...

October 29, 2024 | Tuesday | News
RiboX Therapeutics Secures FDA Clearance for First-Ever Circular RNA Therapy RXRG001 in Phase I/IIa Study

RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics...

October 28, 2024 | Monday | News
Kind Pharmaceutical Secures FDA Orphan Drug Designation for Sickle Cell Disease Treatment AND017

Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing...

October 28, 2024 | Monday | News
Novartis Unveils Promising 12-Month Data for Fabhalta® in C3 Glomerulopathy at ASN Kidney Week 2024

Novartis presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3...

October 28, 2024 | Monday | News
European Commission Approves KEYTRUDA for New Indications in Gynecologic Cancers

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved two new indications for K...

October 25, 2024 | Friday | News
Roche CEO Thomas Schinecker Highlights Strong Q3 Growth Fueled by Innovative Medicines and Diagnostic Solutions

Roche’s latest financial report highlights its robust performance, driven by innovation in its pharmaceutical and diagnostics divisions, while navi...

October 23, 2024 | Wednesday | Company results
BD and Hamilton Robotics Launch Automation-Ready Reagents to Transform Genomic Sequencing Workflows

  Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing&nb...

October 15, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close